New study suggests anti-epileptic medication, Topamax, can improve manic symptoms of bipolar disorder

December 03, 2001

Most study participants report modest weight loss, rather than weight gain caused by many bipolar treatments

Monte Carlo - Nov. 29 - The severity of manic symptoms that plague the victims of bipolar disorder -- which afflicts approximately 1-2 percent of the world population -- was significantly reduced by Topamax® (topiramate) in a multi-centre study of the medication in patients who had a history of poor response or intolerance to mood stabilizers. The study of this potentially new use for Topamax, which is currently approved only for the treatment of various types of epileptic seizures, was presented today at the International Forum on Mood and Anxiety Disorders.

Bipolar disorder is characterized by excessive, disruptive swings in mood, ranging from manic episodes -- marked by extreme agitation, impaired concentration and "racing thoughts" -- to periods of deep depression. Seventy percent of the 61 adults who participated in the 12-week, open-label study experienced an improvement of 50 percent or greater in their scores on the Young Mania Rating Scale -- a widely accepted tool that measures the severity of manic symptoms. In addition, 41 percent met the criteria for remission.

"The data indicate that Topamax may be a promising therapy for the treatment of bipolar disorder, particularly in managing the manic symptoms that can be so destructive episodes," says Eduard Vieta, MD, who conducted the study and is affiliated with the Bipolar Disorders Programme at the University of Barcelona in Spain. "What makes these positive results so compelling is that the study participants were resistant to or couldn't tolerate conventional mood stabilizers."

Thirty-nine percent of the study participants took only Topamax to treat their bipolar disorder during the trial. The remainder added Topamax to one or more other mood-stabilizing medications, including lithium (28%), valproate (16%) and carbamazapine (11%). Many of these and other medications used to treat bipolar disorder cause weight gain, often leading to noncompliance. However, none of the patients who took Topamax in this study gained weight, and more than a third (39%) lost weight -- an average of 2-3 kilograms over the three-month period. Weight loss was most pronounced in individuals with the highest body mass index (a measurement of the proportion of fat compared to muscle).

"The weight gain that is so often associated with many conventional bipolar treatments can be significant health problem, and a barrier to treatment compliance," comments Dr. Vieta. "Not only can it contribute or exacerbate other conditions such as cardiovascular disease, it can significantly undermine these individuals' already-low self-esteem."

In the study, participants were given a starting Topamax dose of 79 mg per day and evaluated after 2, 4 and 12 weeks. The dose was titrated up by 20 to 60 mg every 3 to 7 days until maximum clinical response or optimal tolerability was achieved. The average dose at the end of the study was 214 mg per day. The most common side effects (reported by 5-10 percent of patients) included paraesthesia (tingling sensation), somnolence (sleepiness), nausea, abdominal pain, headache, tremor and cognitive disturbance (such as an impaired ability to concentrate). Only one patient, however, dropped out of the study due to side effects.

Bipolar disorder is difficult to diagnose, since the symptoms may be confused with depression or other mood disorders. Without treatment, the disease can be life threatening. Between 25 and 50 percent of those suffering from the condition attempt suicide, and 10-15 percent of those individuals succeed.

This study led by Dr. Vieta supplements the findings of 10 other open-label trials involving more than 275 patients, all of which suggested that Topamax has mood-stabilizing properties. Janssen-Cilag, which partially supported the Vieta study, and its research affiliate -- the R.W. Johnson Pharmaceutical Research Institute -- is currently conducting large-scale Phase III research into the use of Topamax for the treatment of bipolar disorder.
Topamax is marketed under various brand names in more than 75 countries and to date, has been prescribed to approximately 935,000 patients worldwide. Topamax is available in tablets and in capsules that can be opened and sprinkled onto food for easy swallowing. It was discovered and developed by the R.W. Johnson Pharmaceutical Research Institute, and is marketed internationally by Janssen-Cilag, with the exception of Canada (where it is marketed by Janssen-Ortho) and the United States (Ortho-McNeil Pharmaceutical).

For further details please contact:

Vanessa Leon
T: +44 20 7611 3596

Pam Rasmussen Janssen Pharmaceutica
T: +1 609 730 2986

Ketchum UK

Related Weight Loss Articles from Brightsurf:

Weight loss shouldn't be the goal of PE
For adults, the goal of exercise is often to shed some pounds, but new research from the University of Georgia suggests the objective should be different for kids.

How long should you fast for weight loss?
Two daily fasting diets, also known as time-restricted feeding diets, are effective for weight loss, according to a new study.

Green tea may help with weight loss efforts
In an analysis published in Phytotherapy Research of randomized controlled trials, individuals who consumed green tea experienced a significant decline in body weight and body mass index.

Changing weight-loss strategies, attempts
The proportion of adults who tried to lose weight in the previous year increased from 1999 to 2016 but the findings of this observational study suggest the results may have been unsatisfactory.

Quality of life changes after weight loss
Obesity increases a number of adverse health consequences including reduced health-related quality of life.

Weight loss medicines underutilized by veterans
Despite the availability of new weight management medications and several clinical guidelines recommending their use as part of a comprehensive treatment plan for obesity, a new study has found that their use is extremely low (about one percent) among eligible Veterans.

Is the most effective weight-loss strategy really that hard?
Dietary self-monitoring is the best predictor of weight-loss success. But the practice is viewed as so unpleasant and time-consuming, many would-be weight-losers won't adopt it.

Study: Faster weight loss no better than slow weight loss for health benefits
Losing weight slowly or quickly won't tip the scale in your favor when it comes to overall health, according to new research.

Mindfulness training may help support weight loss
Mindfulness training may improve the effectiveness of intensive weight management programs, according to a small study published in the Endocrine Society's Journal of Clinical Endocrinology & Metabolism.

Does weight loss before surgery provide benefits?
For obese and overweight patients, it is common for various surgical procedures to be deferred until they have lost weight through diet and exercise.

Read More: Weight Loss News and Weight Loss Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to